Apellis Pharmaceuticals APLS announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...

Derek Archila, an analyst from Wells Fargo, maintained the Hold rating on Apellis Pharmaceuticals (APLS – Research Report). The ...

Citi analyst Yigal Nochomovitz has reiterated their bullish stance on APLS stock, giving a Buy rating on September 20. Yigal ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $36.73 which represents a slight increase of $1.10 or 3.09% from the prior close of $35.63. The stock opened at $36.24 ...

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.47, ...

Apellis Pharmaceuticals Inc (APLS) stock saw a decline, ending the day at $38.36 which represents a decrease of $-0.82 or -2.09% from the prior close of $39.18. The stock opened at $38.97 and touched ...

A real-world study of pegcetacoplan for treatment of geographic atrophy showed significantly better outcomes than the pivotal clinical trials in patients who had symptomatic vision loss.